Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesPhathom Pharmaceuticals Inc

Phathom Pharmaceuticals Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
6.19 USD -0.09 ( 1.43%)
Last update at 2026-11-12T15:38:00Z
VOLUME
159362
Market Cap
660.15M

Momentum Score

…

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
6.10
Low
6.34
High
52 Week Price Range
8.07
Low
18.31
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Phathom Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for gastrointestinal motility and acid-related disorders. Its long-term growth may be supported by advancement through clinical trials, potential regulatory approvals, and commercialization or licensing of differentiated treatments that could address unmet needs compared with existing therapies.

The most important investment risks are clinical and regulatory failure, the need for additional financing to fund development, and competitive pressure from established treatments with uncertain market adoption and reimbursement.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
6.28
Dividend Yield
-
Revenue TTM
239.66M
Revenue Per Share
3.06
Gross Profit TTM
198.73M
Debt / Equity
-0.48
ROE
-3489.00%
Net Debt
81.83M
ROCE
-120.48%
Diluted EPS TTM
-1.17

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -221.25M -334.33M -201.59M -197.72M -143.88M
Net income -221.25M -334.33M -201.59M -223.01M -148.09M
Selling general administrative 279.72M 290.66M 117.93M 101.00M 62.74M
Gross profit 152.51M 47.28M 0.52M - -
Reconciled depreciation 0.63M 0.80M 0.57M 0.62M 0.52M
Ebit -153.13M -262.32M -159.62M -172.44M -135.08M
Ebitda -152.50M -261.52M -159.05M -170.42M -137.09M
Depreciation and amortization 0.63M 0.80M 0.57M 2.02M -2.02M
Non operating income net other - - - - -2.02M
Operating income -159.99M -277.47M -167.31M -172.44M -135.08M
Other operating expenses 335.10M 332.72M 167.99M 172.44M 135.08M
Interest expense 68.11M 72.01M 41.97M 27.30M 6.79M
Interest income 7.04M 15.16M 7.88M 2.13M 0.04M
Net interest income -61.07M -56.85M -34.09M -25.17M -6.75M
Income tax expense - - 41.78M 25.28M 4.21M
Total revenue 175.11M 55.25M 0.68M 0.00M 0.00M
Total operating expenses 312.50M 324.75M 167.83M 172.44M 135.08M
Cost of revenue 22.60M 7.97M 0.17M - -
Total other income expense net -61.26M -56.86M -34.28M -25.28M -8.80M
Net income from continuing ops -221.25M -334.33M -201.59M -197.72M -143.88M
Net income applicable to common shares - - - -197.72M -143.88M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 259.15M 378.32M 413.84M 164.81M 189.43M
Other current assets 15.35M 20.87M 13.19M 5.13M 3.27M
Total liab 697.32M 631.90M 486.60M 239.62M 117.28M
Total stockholder equity -438.17M -253.58M -72.76M -74.81M 72.16M
Other current liab 126.41M 74.72M 7.11M 15.53M 13.28M
Common stock 0.01M 0.01M 0.01M 0.00M 0.00M
Capital stock 0.01M 0.01M 0.01M 0.00M 0.00M
Retained earnings -1484.26M -1263.01M -928.68M -727.09M -529.37M
Other liab - - - 7.50M 7.50M
Other assets - - - 0.80M 0.34M
Cash 129.97M 297.26M 381.39M 155.38M 183.26M
Total current liabilities 132.04M 85.73M 38.78M 26.24M 18.92M
Current deferred revenue - - 18.34M - -
Net debt 81.83M -95.35M -242.36M -58.31M -91.92M
Short term debt 0.65M 0.50M 0.73M 0.71M 0.49M
Short long term debt total 211.80M 201.91M 139.03M 97.07M 91.34M
Other stockholder equity 1046.08M 1009.42M 855.92M 652.28M 601.52M
Property plant equipment - - - 3.49M 0.65M
Total current assets 228.97M 360.13M 397.43M 160.51M 186.53M
Net tangible assets - - - -74.81M 72.16M
Net receivables 78.13M 38.80M 1.64M - -
Long term debt 209.09M 201.41M 137.84M 95.26M 89.67M
Inventory 5.52M 3.21M 1.21M - -
Accounts payable 4.98M 10.51M 12.60M 10.00M 5.15M
Accumulated other comprehensive income - - 0.00M - -
Common stock total equity - - - - 0.00M
Retained earnings total equity - - - - -529.37M
Non currrent assets other 26.51M 16.09M 9.93M 0.80M 0.34M
Non current assets total 30.18M 18.18M 16.41M 4.30M 2.90M
Capital lease obligations 2.71M 0.50M 1.19M 1.81M 1.67M
Long term debt total - - - - 89.67M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.14M -1.63M -1.04M -0.33M
Change to liabilities - - - 8.68M -9.63M
Total cashflows from investing activities -0.23M -0.14M -1.63M -1.04M -0.33M
Net borrowings 0.00M 59.40M 39.32M 95.45M 42.76M
Total cash from financing activities -0.29M 182.77M 367.58M 120.04M 44.71M
Change to operating activities - - - -3.24M -17.68M
Net income -221.25M -334.33M -201.59M -197.72M -143.88M
Change in cash -167.29M -84.13M 228.37M -27.53M -104.24M
Begin period cash flow 300.12M 384.26M 155.89M 183.42M 287.50M
End period cash flow 132.83M 300.12M 384.26M 155.89M 183.26M
Total cash from operating activities -166.78M -266.77M -137.58M -146.53M -148.62M
Issuance of capital stock 0.00M 121.78M 155.46M 24.60M 0.00M
Depreciation 0.63M 0.80M 0.57M 0.62M 0.52M
Other cashflows from investing activities -0.23M -0.14M - - -
Change to inventory -11.78M -6.14M -9.44M - -
Change to account receivables -39.33M -37.16M -1.64M - -
Sale purchase of stock - - - - 1.94M
Other cashflows from financing activities -1.93M 1.60M 172.80M 95.45M 97.54M
Change to netincome - - - 43.02M 18.62M
Capital expenditures 0.23M 0.14M 1.63M 1.04M 0.33M
Cash flows other operating - - - - -17.85M
Cash and cash equivalents changes - - - - -104.24M
Change in working capital -12.38M -15.30M -13.64M 5.44M -27.48M
Stock based compensation 28.72M 24.05M 45.02M 24.13M 16.81M
Other non cash items 37.50M 58.01M 32.06M 21.00M 5.41M
Free cash flow -166.78M -266.90M -139.21M -147.57M -148.94M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
PHAT
Phathom Pharmaceuticals Inc		 -0.09
1.43%		 6.19 - 8.20 2.75 25.37 2.87 -2.20
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

100 Campus Drive, Florham Park, NJ, United States, 07932

877 742 8466

https://www.phathompharma.com

371

Name Title Year Born
Ms. Terrie J. Curran Pres, CEO & Director 1969
Mr. David A. Socks Co-Founder & Director 1975
Dr. Azmi Nabulsi M.D., M.P.H. Co-Founder & COO 1960
Mr. Anthony J. Guzzo Chief Accounting Officer 1973
Mr. Aditya Kohli Ph.D. Co-Founder 1988
Ms. Molly Henderson CPA, MBA Chief Financial & Bus. Officer 1971
Mr. Joseph Hand J.D. Chief Admin. Officer NA
Mr. Lawrence Miller Esq., J.D. Gen. Counsel & Sec. NA
Mr. Tom Harris Chief Devel. Sciences Officer NA
Dr. Eckhard Leifke M.D., Ph.D. Chief Medical Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…